non-small cell lung cancer

Jan 4, 2023

FDA Approves Foundation Medicine Blood Test as CDx for Rozlytrek

Dec 22, 2022

Gilead Sciences, Arcus Biosciences Tout Domvanalimab NSCLC Data as Good News for Anti-TIGIT Approach
Premium

Dec 21, 2022

Japanese Lung Cancer Genomic Screening Project Expands in Asia-Pacific

Dec 19, 2022

AstraZeneca's Imfinzi Fails to Meet Primary Endpoint in PD-L1-high NSCLC

Dec 14, 2022

Functional Precision Medicine Firm Kiyatec Raises $18M in Series C Funding Round

Dec 13, 2022

FDA Approves Mirati's Krazati for Advanced KRAS-Mutated Lung Cancer

Dec 8, 2022

Mirati Therapeutics Sees First-Line Potential in Adagrasib-Keytruda Combo
Premium

Dec 7, 2022

Dragonfly Therapeutics Begins Phase II Trial of HER2-Targeted NK-Cell Engager

Nov 30, 2022

Addario Lung Cancer Medical Institute Begins Study Exploring KRAS Inhibitor Resistance

Nov 29, 2022

Alaunos Therapeutics Expecting $15.7M in Common Stock Offering

Nov 28, 2022

Studies Assess Tumor Aneuploidy to Guide Immunotherapy Treatment

Nov 28, 2022

Exscientia Receives Regulatory Nod to Start AI-Aided Phase I/II Trial

Nov 16, 2022

NICE Approves Takeda's Exkivity for EGFR Exon 20 Insertion-Positive NSCLC

Nov 11, 2022

J Ints Bio to Begin US Trial of JIN-A02 for EGFR C797S-Mutated NSCLC

Nov 10, 2022

Diaceutics, PMC Identify Ways Lung Cancer Patients Are Losing Out on Precision Oncology Therapies
Premium

Nov 4, 2022

Lumakras Sales More Than Double in Q3 2022 as Amgen's Overall Revenues Decline 1 Percent
Premium

Nov 1, 2022

Monte Rosa Doses First Patient in Phase I/II Trial of MRT-2359

Oct 26, 2022

Hedera Dx Hopes to Hasten Liquid Biopsy Adoption in Europe With Streamlined Platform
Premium

Oct 26, 2022

Yale Spinout Modifi Biosciences Nets $2.4M From NCI to Advance Targeted Cancer Drugs Toward Clinic

Oct 25, 2022

ImaginAb Doses First Patient in Study of CD8-Targeted PET Imaging Agent in Australia